Clinical Trials
10 trialsNCT06003231 2026-06-01
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
Phase 2 Active not recruiting
NCT07608224 2026-05-27
HOPE-07-MIBC
West China Hospital
Phase 2/3 Not yet recruiting
NCT05831878 2026-05-13
RC48-ADC in HER2-low Advanced Breast Cancer
RenJi Hospital
Phase NA Recruiting
NCT06157892 2026-05-05
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Seagen Inc.
Phase 2 Recruiting
NCT04879329 2026-04-21
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Seagen Inc.
Phase 2 Recruiting
NCT06966453 2026-04-21
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Pfizer
Phase 1/2 Recruiting
NCT05911295 2026-04-20
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Seagen Inc.
Phase 3 Active not recruiting
NCT07509424 2026-04-03
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07507526 2026-04-02
DTP-HER2
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07474064 2026-03-17
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting